Publications by authors named "D E Weiner"
Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteers.
Christian J Maine Shigeki J Miyake-Stoner Darina S Spasova Gaelle Picarda Annie C Chou David B Weiner
Nat Commun
January 2025
Self-replicating RNA (srRNA) technology, in comparison to mRNA vaccines, has shown dose-sparing by approximately 10-fold and more durable immune responses. However, no improvements are observed in the adverse events profile. Here, we develop an srRNA vaccine platform with optimized non-coding regions and demonstrate immunogenicity and safety in preclinical and clinical development.
View Article and Find Full Text PDFBackground: Patients treated with maintenance hemodialysis (HD) are at high risk of death from a variety of causes.
Methods: To identify markers (i.e.
Article Synopsis
- Glioblastoma multiforme (GBM) presents a challenge for treatment due to its antigenic variability, prompting researchers to develop multivalent immunotherapies that target multiple tumor antigens to improve effectiveness.
- The study introduces a new class of antibodies called DNA-encoded tri-specific T-cell engagers (DTriTEs) that target two specific GBM antigens and engage T cells, showing promising in vitro and in vivo results.
- The leading DTriTE construct, DT2035, not only significantly reduced tumor burden and improved survival rates in mouse models but also showed sustained expression and induced strong immune responses, making it a potential game-changer for GBM treatment.